

Annual Report

The difference we made in 2022



We're Cardiomyopathy UK

We save and improve the lives of people affected by cardiomyopathy. Our vision is a world where everyone affected by cardiomyopathy should live a long and fulfilling life. In pursuit of this vision:



We raise awareness of the condition so that more people know the signs and symptoms and can be diagnosed early.



We campaign to improve access to quality treatment that meets the needs of people with cardiomyopathy.



We promote clinical research to advance the development of new treatments and provide hope for the future.



We support people affected by cardiomyopathy, every step of the way, so that nobody has to face cardiomyopathy alone.

1 in 250 people have cardiomyopathy.
That's approximately 266,000 people in
the UK currently living with the condition.



Contents



3 Introduction from our Chair of Trustees

6 Our Achievements in 2022

11 Funding our Work

14 Our Ambitions for 2023

17 Trustees' Report

22 Independent Auditor's Report

28 Financial Statements

32 Notes to the Financial Statements



A Message From Our Chair



Cardiomyopathy UK is proud to be the specialist charity for people affected by the heart muscle disease, cardiomyopathy. Our vision is that those affected by cardiomyopathy should live a long and fulfilling life.



As I begin my report, it is with a heavy heart that I acknowledge that on May 16th 2022, one of our longest serving trustees Christopher Horwood (Chris) sadly passed away. Chris joined the Board in 2008 and was highly regarded by his fellow trustees.

As Chris's wife, Esther said: "After 20 years of fighting illness, he simply didn't have the strength to go on". We consider ourselves lucky to have shared Chris with Esther and the family.

The charity has continued to develop and grow its services, helping patients and their families to understand, cope with and work through the challenges they are experiencing. This past year we have been able to re-establish our face-to-face Support Group Meetings, Board Meetings, and our National Conference, with circa 300 attendees.

In March we participated in the first meeting held by NHS England to review, improve, and update the service specification for Inherited Cardiac Conditions Services in the NHS. We continue to be engaged

with this work, to ensure that the requirements outlined in our Change Agenda are incorporated into the new Inherited Cardiac Conditions specification.

Our national survey in August received 602 responses. We were able to use some of the detailed analysis to feed into the NICE appraisals of Mavacamten. Our research submission to NICE on Mavacamten, for the treatment of obstructive hypertrophic cardiomyopathy, was received extremely favourably. We also submitted a scoping document on the proposed use of Evusheld to prevent Sars-Covid-2 in immunosuppressed and transplant patients.

The expansion of our research and policy work enables us to raise the profile of the charity and cardiomyopathy within medical and healthcare environments. By developing policies and conducting research, we can have an even greater impact on improving the care and quality of life relating to all aspects of cardiomyopathy and myocarditis.

A Message From Our Chair



The first ever International Cardiomyopathy Awareness Week campaign took place in June. The campaign was led by the Cardiomyopathy Patient Council of the Global Heart Hub. The Global Heart Hub is a group of 10 cardiomyopathy charities from around the world, including Cardiomyopathy UK. The campaign aimed to raise awareness and understanding of what cardiomyopathy is, the signs and symptoms and the importance of knowing your family history. The campaign received a fantastic response.

We were delighted when the CureHeart Project was announced as the winners of the Big Beat Challenge, being awarded £30m. The project aims to find the world's first cure for inherited heart muscle diseases. We are pleased to be working with this exciting and ground-breaking project.

I continue to be inspired by the professionalism, dedication, determination, and hard work of our staff team, ably led by our Chief Executive, Joel Rose. Together with our committed volunteers who never fail to step up and are involved in a wide range of events and services, from fundraising to committees, support groups and various projects, they have ensured that the cardiomyopathy community has been

provided with a wide range of much needed services and support.

Thanks to these combined efforts, I am pleased to be able to report that we ended the year in a strong financial position, with healthy reserves, continued growth and achieving £1 million in net income for only the second time in the history of the charity.

I would like to take this opportunity to thank and commend my fellow trustees, presidents, staff, volunteers, and professionals for their time and the work they have undertaken this past year. Together they have enabled us to continue to support our community and make a difference in people's lives.

As we engage in the process of developing our new Five-Year Strategic Plan January 2024-December 2028, I am optimistic for the future and look forward to the new and exciting opportunities that lie ahead. There is still a great deal of work to be done to improve the diagnosis, care, and treatment that people with cardiomyopathy receive, as our recent survey has shown.

Rita Sutton,
Chair of the Board of Trustees

Achievements in 2022



Providing support and information

Our support and information services aim to help people affected by cardiomyopathy feel more informed, less scared and better able to cope day to day.

Our support group volunteers did a fantastic job in 2022. Their hard work meant that we could offer a mixture of online and face-to-face groups so that more people could access this fantastic service. One attendee told us:

“Thanks to the group I have made some real friends, who “get it” in a way that not even my family or closest friends do”

As well as our online and face to face support groups, our peer support volunteers continued to help people and our closed Facebook group continued to grow.

Our Cardiomyopathy UK Specialist Nurses continued to be busy on the Helpline supporting people over the phone and online. 96% of our callers said the call was “very helpful” One caller put it simply:

“Thank you so much for listening what would we do without your charity.”

180



support group meetings were held across our 38 groups

1,124

people were supported online and on our helpline by our Specialist Nurses



317



people were supported by our Telephone Peer Support Volunteers

2,264



Active members on our closed Facebook group

Achievements in 2022



One of the highlights of the year had to be our National Conference where we were able to meet in person once again after two years of the pandemic. We had a packed programme with session covering all aspects of cardiomyopathy and living with the condition day to day. Feedback from the event was overwhelmingly positive;

“The whole day was extremely informative, relevant warm and friendly”

“I feel more positive and armed with more information”

“I feel more empowered, like I have more control”

“I have more information now, I don't feel so alone”

Raising Awareness

In 2022 we took part in the first ever International Cardiomyopathy Awareness Week campaign. We worked as part of a network of cardiomyopathy charities from around the world to produce a simple social media campaign to highlight the symptoms of cardiomyopathy and the importance of knowing any history of heart disease in your family.



100%

of attendees said that they knew more about cardiomyopathy as a result of attending the conference.

The campaign's video, resources and materials, in 5 different languages reached over



6 million people

Achievements in 2022



Promoting Research to improve the care and treatment of people with cardiomyopathy

In 2022 we were able to increase the work we do to shape clinical research as well as do more work to improve our understanding of the impact of cardiomyopathy and how accessing care and treatment has changed since the pandemic.

We were really pleased that we received a fantastic response to our national survey. The results have been incredibly instructive and will arm us with the information that we need when we advocate for better services for people affected by cardiomyopathy. You can read more about the survey and the key results on our website.

A major highlight of 2022 was the announcement that the CureHeart research team, of which we are part, had been successful in the British Heart Foundation's "Big Beat Challenge" winning a £30million pound research grant. As part of the winning team, our job will be to ensure that the project stays focused on the need to deliver results for people with cardiomyopathy and that the cardiomyopathy community is kept up to date with progress.

During the year we were able to support researchers on a wide

range of projects from using simple technology to monitor arrhythmias to measuring blood vessels in the tongue for early signs of heart failure. We also continued to work with the Heart Hive team to promote involvement in research and encourage more people to sign up to their research matching website at:

 www.thehearthive.org



people filled out our national survey



CureHeart was awarded a £30 million research grant after winning the British Heart Foundation's 'Big Beat Challenge'

Achievements in 2022



Advocating for people with cardiomyopathy

2022 saw our advocacy work continue to grow. It was especially pleasing to see how our Change Maker volunteers were able to keep up momentum and make significant and valuable changes to how care and treatment is provided in their area and nationwide. During the year our volunteers, amongst other things, participated in GP's training programmes, pushed for better use of electronic patient records, reviewed advice sheets and patient letters and represented Cardiomyopathy UK at national clinical conferences.


We also worked hard to ensure that we could give a true account of the impact of cardiomyopathy as part of the National Institute for Health and Care Excellence (NICE) review of a new medicine for people with obstructive hypertrophic cardiomyopathy. In 2023, NICE will be deciding whether to make this new medicine available on the NHS and we want to make sure that they have the information that they need to make the right decision.

We all know that cardiomyopathy comes with a range of related conditions and issues. This means it is important that the cardiomyopathy voice is heard in discussions about, for example, heart failure,

transplantation, mental wellbeing, genetics and access to benefits. In 2022 we worked in collaboration with other charities and organisations to engage in these discussion and represent the unique needs of our community.

Working with healthcare professionals

It has been our long-term aim to ensure that health care professionals are better able to diagnose cardiomyopathy, provide appropriate support and ensure that at-risk family members are identified. There is still a great deal to do in this area, but our online Medical Education work is starting to make a difference. In 2022 we were able to launch two more accredited online learning courses. We now have over 200 clinicians making use of this important resource and telling us how much their knowledge and practice has improved.



Achievements in 2022



Working as part of the wider cardiomyopathy community

In 2022, we continued to play our part in the wider international cardiomyopathy community as an active part as a member of the Cardiomyopathy Council, a network of 15 cardiomyopathy focused charities from around the world that we founded. In addition to running the first ever international cardiomyopathy awareness campaign the council also worked together to agree best practice in working with clinical researchers and shared ideas on how access to research trials could be improved.

During the year, we also worked closely with the International Cardiomyopathy Network (ICoN), a network of leading cardiomyopathy clinicians and researchers, to help them set out their objectives and secure funding.


**International
Cardiomyopathy
Network | ICoN**



Ensuring good governance

In 2022, our Trustees continued their commitment to ensuring that the charity is well managed and governed appropriately. We worked with the National Council of Voluntary Organisations (NCVO) to review our governance processes and policies and, thanks to the feedback and support of NCVO, trustees are confident that we remain efficient, well managed and best placed to serve the cardiomyopathy community.

The first ever international cardiomyopathy awareness campaign ran across...



9
countries

and reached over...




6
million
people

Funding our work

Income & Expenditure



Income



Community and
Challenge Events

39%

Donations

10%

Legacies

9%

Trusts and Foundations

25%

Companies

17%

Expenditure

Providing Support

36%

Raising Funds

32%

Research

10%

Public and Professional
Education


12%

Governance and
Administration

7%

Campaigning

3%



Funding our work



We are delighted to report that 2022 was a successful year for our fundraising. Despite the challenging fundraising environment, income for the year grew to £1,031,133 thanks to the generosity of our supporters and commitment of our volunteer fundraisers. Unrestricted income recovered well in 2022. In 2021, restricted income made up 42% of our total income. In 2022 we were able to shift this balance to a more sustainable position with restricted income only making up 33% of our total income.

Although it took some time in early 2022 for the events industry to regain momentum and return to pre-pandemic levels of activity, we saw the broadest range of activity since the pandemic began. Our fantastic team of London Marathon runners raised over £152,000. It was wonderful to see our runners able to hold public and social events as part of their marathon fundraising once again. We also saw supporters taking part in various local runs, cycles and skydives. International events returned too, including two superstar fundraisers, Dougie and Pete, who were finally able to take on the Marathon des Sables in Morocco, raising £26,000.

Throughout the year, our wonderful community raised funds by organising

their own events including golf days, race nights, step challenges, coffee morning to name just a few. It was lovely also to have the return of schools fundraising for us, which hasn't been possible for the past two years.

Although we no longer faced the challenges of pandemic restrictions, the impact of the cost-of-living crisis on fundraising in 2022 was clear. This was most notable in regular giving and donations from individuals where income fell, particularly in the latter half of the year. Our Fundraising Team were conscious of the very real impact of the cost-of-living. We saw instances where supporters struggled to meet sponsorship targets due to economic pressures, stress and even redundancies. In response, our fundraising team provided more frequent and more-hands-on support than ever before. This included our team directly addressing the discomfort that fundraisers were feeling around asking for donations by providing template wording, impact graphics, tips and reassurance.

Funding our work



Fundraising responsibly

We are committed to raising funds in a responsible and sustainable way. Our fundraising is conducted either directly by our fundraising staff team or by volunteer fundraisers under their support and guidance. We do not use the services of third-party professional fundraisers or fundraising companies. We work to ensure that our fundraising activity meets the best practice standards laid out by the Charity Commission and the Fundraising Regulator and in 2022 we received no complaints regarding our fundraising activity. Our work is also conducted in line with all GDPR regulations and we are signed up to the Fundraising Preference Service. The Fundraising Preference Service's purpose is to guard against unreasonable intrusion on privacy, unreasonable persistent approaches for donations or placing undue pressure on a person to give money or other property.

Thank you

Thank you to every single fundraiser, donor and volunteer who has raised funds that enable us to continue saving and changing the lives of people affected by cardiomyopathy, now and in the future.

We would also like to give our heartfelt thanks for every donation

made in memory of a loved one, including funeral collections, in memory events, donations and gifts given in Wills. These donations create a lasting legacy by moving us a step closer towards our vision of a world where everyone affected by cardiomyopathy can live a long and full life.

In 2022 we were grateful for new and continued support from: The National Lottery Community Fund, The Masonic Charitable Foundation, Max's Foundation, Browns Solicitors and the CAF Resilience Fund.



Ambitions for 2023



Providing Support and Information

In 2023 we will work to ensure that more people, and from a wider range of communities, are able to access our support and information services. We also want to make sure that our services can meet the changing needs of our community and support people with cardiomyopathy, and their loved ones, every step of the way.

In 2023 we aim to reach more people across the UK by working with local hospitals to ensure that all cardiomyopathy patients are made aware of the help that we can provide.

We also recognise that the cost-of-living crisis is having an especially severe impact on many people with cardiomyopathy. In 2023 therefore we will review the services that we provide for people who are struggling to access statutory benefits because the impact of their condition is not being properly understood. We will also continue to grow our support group and peer support networks so that more people have the opportunity to speak to someone who understands what they are going through and test new approaches to addressing mental health needs of our community.

Raising Awareness

In 2023 we hope to build on the success of the first ever international cardiomyopathy awareness campaign held last year. We will once again be working with cardiomyopathy charities from around the world to highlight the importance of genetic testing and family screening in cardiomyopathy.

We will also continue to grow our online presence ensuring that we can make best use of social media platforms to reach new audience with our awareness raising messages. In addition to this, we will continue to seek opportunities to raise the profile of cardiomyopathy and our work in the media.



Ambitions for 2023



Promoting Research to improve the care and treatment of people with cardiomyopathy

In 2023 we aim to continue to grow our research activity and play a significant role in the cardiomyopathy research community so that clinical research meets the needs of people with cardiomyopathy and so that we can increase our own understanding of the condition.

We plan to work with The James Lind Alliance to bring together all the key stakeholders in cardiomyopathy research to identify research priorities and increase our own capacity to support research projects by recruiting and training more research volunteers. We also hope to invest in communications to ensure that research opportunities can be promoted, and findings disseminated to a wider audience.

As well as supporting clinical researchers, in 2023 we plan to undertake our own research into how people with cardiomyopathy access genetic testing and we will be publishing the results of our national survey.

Raising Awareness

We are proud of the advocacy work that we undertook in 2022 and the difference that we were able to make along with our team of volunteer

“Change Makers”. It is clear however that in 2023 we must continue to grow the Change Maker volunteer network and do more to help volunteers push for improvements in their local health services in line with the agreed national “Change Agenda”.

As well as this, in 2023 we will keep working alongside other national and international charities and networks to have a more impactful collective voice and ensure that the needs of people with cardiomyopathy are heard by policymakers across all regions of the UK.

With NICE due to evaluate the first cardiomyopathy specific treatment, and other new drugs on the horizon, we will also continue to provide robust qualitative and quantitative evidence to NICE and other technology appraisers to give a true account of the impact of cardiomyopathy.





Working with healthcare professionals

Following the successful launch of our online medical education work, in 2023 we will keep growing this important learning resource and publish additional units covering genetics in cardiomyopathy and arrhythmogenic cardiomyopathy.

We will also explore new opportunities to work with other partners to do more to reach healthcare professionals and especially GPs, so that we can tackle the unacceptably high levels of misdiagnosis.

Working as part of the wider cardiomyopathy community

Now that the ICoN group has been able to secure funding for their work, this important new organisation will begin its agreed programme of activity for 2023. We will continue to support their work and ensure that the views of people with cardiomyopathy are central to their discussions.

We will also continue to play our part as a member of the cardiomyopathy council which aims to undertake further awareness raising activities in 2023 along with work to help bring together international research efforts.

Ensuring good governance

2023 will be the final year of our current strategic plan. This means that during the year we will be working to gather the views of our key stakeholders to develop our strategy for the next five years. In 2023 Trustees will continue to regularly review performance against objectives and, where necessary, bring onto the board new trustees so that the trustee team have all the skills, knowledge and experience necessary to lead the charity.





Structure, Management and Governance

The charity is controlled by its governing document and constitutes a charitable incorporated organisation. The charity is governed by its constitution adopted on 5 November 2015.

The charity continues to review and, where necessary, improve its trustee induction and training resources to ensure that new trustees are equipped to support the work of the charity to their maximum ability. Appropriate policies and procedures have been put in place to ensure good governance including financial management, data protection and employment practice. Trustees maintain a risk register and work with the Chief Executive to ensure that strategies are in place to mitigate against identified risks.

In 2022, Trustees continued to work in accordance with the charity's three-year plan for the years 2021 to 2023. This plan was developed in 2020 with input from staff, clinicians and the wider cardiomyopathy community and is available on the Cardiomyopathy UK website.

Financial Review

Trustees are proud to report that despite the huge challenges faced by all in 2022, the charity was able to further strengthen its financial position. This was achieved by increasing unrestricted income from the community and challenge event fundraising, thanks in a large part to a record London Marathon team, while at the same time managing costs and continuing to build support from trusts and companies.

Trustees note that the key financial challenge for 2023 will be for the charity to maintain levels of restricted income while at the same time growing unrestricted income at a time when many supporters are facing significant increases in their own cost of living. Trustees are hopeful that this can be achieved especially as the charity's network of supporters, fundraising volunteers and challenge eventers remain engaged with the charity.



Partnerships

The charity works closely with expert clinicians from a number of NHS Trusts to help ensure that its work is clinically appropriate and that it can reach as many people with cardiomyopathy as possible.

During the year the charity continued to work with its President, Prof. Perry Elliott to develop the International Cardiomyopathy Network (ICoN), a registered UK charity. Cardiomyopathy UK's Chief Executive supported ICoN in their efforts to raise funding from corporate partners and provided strategic advice and patient insight as part of a shared commitment to improving the level of cardiomyopathy knowledge among clinicians, developing best practice and fostering research that will make a real difference to the lives of people with the condition. During the year ICoN made a payment of £15,000 to the charity to cover the costs incurred in providing this support.

The charity continued to have a positive relationship with The British Heart Foundation, The Pumping Marvellous Foundation, Gene People, Heart UK and a number of other charities that provide support and information relating to heart diseases. Where possible, the charity works in collaboration with these charities.

During 2022 the charity received funding from five pharmaceutical companies (Sanofi, Pfizer, Alnylam, Tenaya and Bristol Myers Squibb) who have developed or who are developing treatments used by people with cardiomyopathy. The total income from these companies was £131,340; under 15% of the charity's total income. Income from these sources covered the costs associated with the charity's medical education project, advocacy project, research and awareness raising and service delivery work. All funding was provided in accordance with the Association of British Pharmaceutical Industry code of practice and the charity's own policy on working with the pharmaceutical industry which is available at:

 www.cardiomyopathy.org/about-us/our-approach

This policy is designed to ensure the charity's independence.



Reserves Policy

The charity aims to maintain unrestricted reserves at a level that equates to around six to nine months of normal unrestricted expenditure. Trustees believe this to be a prudent amount given that the charity operates in a competitive environment and, as the leading specialist provider of support services for people affected by cardiomyopathy, there is a duty to ensure that it can maintain core services for individuals in need.

Towards the end of the year the charity was notified about two legacies with a total value of £95K. This resulted in unrestricted reserves increasing to 11 months of normal expenditure at the end of the year. Trustees however are aware that the charity faces increased unrestricted costs in 2023 as a number of restricted funding grants are due to come to an end during the year and costs will be covered from unrestricted funds. Trustees expect that unrestricted reserves will return to the six to nine month target by the end of 2023.

Public Benefit

Cardiomyopathy UK confirms that in setting its programme of activity, it has had due regard to the Charity Commission's general guidance on public benefit. The programme of activity also conforms to the charity's charitable objectives and aims. No persons are excluded from the work of the charity on grounds of gender, race or religion.

Reference and Administrative Details



Board of Trustees:

T Amiss
M Bloom (appointed March 2023)
T Bueser
S Cornish MBE (appointed July 2023)
G Favier
C Horwood (Deceased May 2022)
S Kirkham MC
I McPherson OBE
E Jarman
E Power (resigned September 2022)
M Rees (appointed July 2023)
A Smith
R Sutton (Chair)
P Thomas (Treasurer)

Chief Executive Officer:

Mr J Rose

Principal Address:

75A Woodside Road
Amersham
Buckinghamshire, HP6 6AA

Auditors:

Seymour Taylor Limited
57 London Road
High Wycombe
Buckinghamshire, HP11 1BS

Charity Number:

1164263

Bankers:

Charity Aid Foundation Limited
Kings Hill
West Malling
Kent, ME19 4TA

Lloyds
82 High Street
Rickmansworth
Hertfordshire, WD3 1AG

Reference and Administrative Details



The trustees are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice). The law applicable to charities in England and Wales, the Charities Act 2011, Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charity for that period.

In preparing those financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charity SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the board of trustees on the 9th of September 2023 and signed on its behalf by Rita Sutton, Chair of Trustees

Rita Sutton

Report Of The Independent Auditors To The Trustees Of Cardiomyopathy UK



Opinion

We have audited the financial statements of Cardiomyopathy UK (the ‘charity’) for the year ended 31 December 2022 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charity’s affairs as at 31 December 2022 and of its incoming resources and application of resources, for the year then ended;
 - have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice;
- and
- have been prepared in accordance with the requirements of the Charities Act 2011.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors’ responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Report Of The Independent Auditors To The Trustees Of Cardiomyopathy UK



Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Report Of The Independent Auditors To The Trustees Of Cardiomyopathy UK



Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Charities (Accounts and Reports) Regulations 2008 requires us to report to you if, in our opinion:

- The information given in the Report of the Trustees is inconsistent in any material respect with the financial statements; or
- Sufficient accounting records have not been kept; or
- The financial statements are not in agreement with the accounting records and returns; or
- We have not received all the information and explanations we require for our audit.

Responsibilities of trustees

As explained more fully in the Statement of Trustees' Responsibilities, the trustees are responsible for the preparation of the financial statements which give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters

related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

Report Of The Independent Auditors To The Trustees Of Cardiomyopathy UK



Our responsibilities for the audit of the financial statements

We have been appointed as auditors under Section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Identifying and assessing potential risks related to irregularities

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws

and regulations, we considered the following:

- Results of our enquiries of management about their own identification and assessment of the risks of irregularities;
- Any matters we identified having made enquiries of management about their policies and procedures relating to:
 - Identifying, evaluating and complying with laws and regulations and whether they were aware of any instances of non-compliance;
 - Detecting and responding to the risks of fraud and whether they have knowledge of any actual, suspected or alleged fraud;
 - The internal controls established to mitigate risks of fraud or non-compliance with laws and regulations;
 - The matters discussed among the audit engagement team regarding how and where fraud might occur in the financial statements and any potential indicators of fraud.

As a result of these procedures, we considered the opportunities and incentives that may exist within the organisation for fraud. In common with all audits under ISAs (UK), we are also required to perform specific procedures to respond to the risk of management override.

Report Of The Independent Auditors To The Trustees Of Cardiomyopathy UK



Identifying and assessing potential risks related to irregularities - continued

We also obtained an understanding of the legal and regulatory frameworks that the company operates in, focusing on provisions of those laws and regulations that had a direct effect on the determination of material amounts and disclosures in the financial statements. The key laws and regulations we considered in this context included the UK Companies Act and local tax legislation.

In addition, we considered provisions of other laws and regulations that do not have a direct effect on the financial statements but compliance with which may be fundamental to the charities ability to operate.

Audit response to risks identified

As a result of performing the above, our procedures to respond to risks identified included the following:

- reviewing the financial statement disclosures and testing to supporting documentation to assess compliance with provisions of relevant laws and regulations described as having a direct effect on the financial statements;
- enquiring of management concerning actual and potential litigation and claims;

- performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud;
- And in addressing the risk of fraud through management override of controls, testing the appropriateness of journal entries and other adjustments; assessing whether the judgements made in making accounting estimates are indicative of a potential bias; and evaluating the business rationale of any significant transactions that are unusual or outside the normal course of business.

We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team members and remained alert to any indications of fraud or non-compliance with laws and regulations throughout the audit.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Independent Auditors.

Report Of The Independent Auditors To The Trustees Of Cardiomyopathy UK



Use of our report

This report is made solely to the charity's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Seymour Taylor Limited, Statutory
Auditor
57 London Road
High Wycombe
Buckinghamshire
HP11 1BS

9th September 2023

Statement Of Financial Activities For The Year Ended 31 December 2022



	Notes	Unrestricted fund £	Restricted funds £	31.12.22 Total funds £	31.12.21 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies	2	650,719	245,013	895,732	815,672
Charitable activities					
Providing support	4	-	21,100	21,100	21,100
Public and medical education		36,808	15,000	51,808	48,800
Research		-	62,300	62,300	59,906
Investment income	3	193	-	193	-
Total		<u>687,720</u>	<u>343,413</u>	<u>1,031,133</u>	<u>945,478</u>
EXPENDITURE ON					
Raising funds	5	287,838	1,326	289,164	276,593
Charitable activities					
Providing support	6	90,009	233,301	323,310	318,800
Public and medical education		85,679	19,379	105,058	93,226
Campaigning		18,853	8,536	27,389	41,834
Research		25,150	59,983	85,133	94,118
Other		57,109	5,050	62,159	76,679
Total		<u>564,638</u>	<u>327,575</u>	<u>892,213</u>	<u>901,250</u>
NET INCOME					
Transfers between funds	16	123,082 (18)	15,838 18	138,920 -	44,228 -
Net movement in funds		<u>123,064</u>	<u>15,856</u>	<u>138,920</u>	<u>44,228</u>
RECONCILIATION OF FUNDS					
Total funds brought forward		393,910	173,052	566,962	522,734
TOTAL FUNDS CARRIED FORWARD		<u><u>516,974</u></u>	<u><u>188,908</u></u>	<u><u>705,882</u></u>	<u><u>566,962</u></u>

The notes form part of these financial statements

Balance Sheet

31 December 2022



	Notes	Unrestricted fund £	Restricted funds £	31.12.22 Total funds £	31.12.21 Total funds £
FIXED ASSETS					
Tangible assets	12	4,882	-	4,882	8,871
CURRENT ASSETS					
Debtors: amounts falling due within one year	13	265,427	-	265,427	244,659
Debtors: amounts falling due after more than one year	13	4,006	-	4,006	29,006
Cash at bank and in hand		300,608	188,908	489,516	356,431
		<u>570,041</u>	<u>188,908</u>	<u>758,949</u>	<u>630,096</u>
CREDITORS					
Amounts falling due within one year	14	(57,949)	-	(57,949)	(72,005)
NET CURRENT ASSETS		<u>512,092</u>	<u>188,908</u>	<u>701,000</u>	<u>558,091</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>516,974</u>	<u>188,908</u>	<u>705,882</u>	<u>566,962</u>
NET ASSETS		<u>516,974</u>	<u>188,908</u>	<u>705,882</u>	<u>566,962</u>
FUNDS	16				
Unrestricted funds				516,974	393,910
Restricted funds				188,908	173,052
TOTAL FUNDS				<u>705,882</u>	<u>566,962</u>

The financial statements were approved by the Board of Trustees and authorised for issue on 9th September 2023 and were signed on its behalf by:

RSJ

Mrs R Sutton - Trustee

The notes form part of these financial statements

Cash Flow Statement

For The Year Ended 31 December 2022



	Notes	31.12.22 £	31.12.21 £
Cash flows from operating activities			
Cash generated from operations	1	134,428	(79,637)
Net cash provided by/(used in) operating activities		<u>134,428</u>	<u>(79,637)</u>
Cash flows from investing activities			
Purchase of tangible fixed assets		(1,536)	(4,617)
Interest received		193	-
Net cash used in investing activities		<u>(1,343)</u>	<u>(4,617)</u>
Change in cash and cash equivalents in the reporting period			
		133,085	(84,254)
Cash and cash equivalents at the beginning of the reporting period			
		<u>356,431</u>	<u>440,685</u>
Cash and cash equivalents at the end of the reporting period			
		<u><u>489,516</u></u>	<u><u>356,431</u></u>

The notes form part of these financial statements

Notes To The Cash Flow Statement For The Year Ended 31 December 2022



1. RECONCILIATION OF NET INCOME TO NET CASH FLOW FROM OPERATING ACTIVITIES			
		31.12.22	31.12.21
		£	£
Net income for the reporting period (as per the Statement of Financial Activities)		138,920	44,228
Adjustments for:			
Depreciation charges		5,525	4,603
Interest received		(193)	-
Decrease/(increase) in debtors		4,232	(107,751)
Decrease in creditors		(14,056)	(20,717)
		<u>134,428</u>	<u>(79,637)</u>
Net cash provided by/(used in) operations		<u>134,428</u>	<u>(79,637)</u>
2. ANALYSIS OF CHANGES IN NET FUNDS			
	At 1.1.22	Cash flow	At 31.12.22
	£	£	£
Net cash			
Cash at bank and in hand	356,431	133,085	489,516
	<u>356,431</u>	<u>133,085</u>	<u>489,516</u>
Total	<u>356,431</u>	<u>133,085</u>	<u>489,516</u>

The notes form part of these financial statements

Notes To The Financial Statements For The Year Ended 31 December 2022



1. Accounting Policies

Basis of preparing the financial statements

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

Cardiomyopathy UK is a charity limited by guarantee and incorporated in England and Wales. The charity's principal address is 75A Woodside Road, Amersham, Buckinghamshire, HP6 6AA. The registered charity number is 1164263.

The presentation currency of these financial statements is Sterling (£), being the currency of the primary economic market in which the entity operates. All amounts in these financial statements have been rounded to the nearest pound unless stated otherwise.

The significant accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

Notes To The Financial Statements For The Year Ended 31 December 2022



1. Accounting Policies -continued

Allocation and apportionment of costs

Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with use of the resources.

Salaries have been apportioned in accordance with the duties to which they relate.

Premises costs have been apportioned on the basis of percentage of floor space used.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Computer equipment - at variable rates on reducing balance

Taxation

The charity is exempt from tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or

when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Pension costs and other post-retirement benefits

The charity operates a defined contribution pension scheme. Contributions payable to the charity's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

Financial instruments

The charity has applied the provisions of Section 11 "Basic Financial Instruments" and Section 12 "Other Financial Instrument Issues" of FRS 102 to its financial statements.

Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as either financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.



1. Accounting Policies - continued

Debtors and creditors due within one year

Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in the Statement of Financial Activities in administrative expenses.

Cash and cash equivalents

Cash and cash equivalents in the Statement of Financial Position comprise cash at bank and in hand and short term deposits with an original maturity date of three months or less. Bank overdrafts are disclosed within creditors on the Statement of Financial Position.

Notes To The Financial Statements For The Year Ended 31 December 2022



2. Donations and legacies

	2022 £	2021 £
Donations	143,430	192,761
Grants and legacies	354,999	361,996
Fundraising	<u>397,303</u>	<u>260,915</u>
	<u>895,732</u>	<u>815,672</u>

Grants received included above are as follows:

	Unrestricted £	Restricted £	2022 Total £	2021 Total £
Browns Solicitors - Helpline	-	30,000	30,000	64,800
Browns Solicitors - Advocacy	-	50,400	50,400	-
Alexander Jansons Fund	-	35	35	(290)
BBC Children in Need	-	-	-	23,925
Big Lottery Fund - Community Peer Support	-	44,918	44,918	58,821
Heart Hive	-	-	-	(1,891)
Max's Foundation	-	14,776	14,776	-
Masonic Charitable Fund	-	20,000	20,000	-
Burdett Trust	-	2,306	2,306	2,203
Arrhythmogenic ACT	-	57,628	57,628	57,628
CAF Resilience Fund	-	10,000	10,000	10,000
CAF Main Fund	-	14,950	14,950	44,850
The Girdler's Company Charitable Trust	-	-	-	1,450
The Moss Family Charitable Trust	1,000	-	1,000	-
Edith Florence Spencer Memorial Trust	-	-	-	11,000
DHPA Project	13,000	-	13,000	-
	<u>14,000</u>	<u>245,013</u>	<u>259,013</u>	<u>272,496</u>
Total Grants				
			<u>95,986</u>	<u>89,500</u>
Total Legacies			<u>342,399</u>	<u>361,996</u>

Notes To The Financial Statements For The Year Ended 31 December 2022



3. Investment income

	31.12.22	31.12.21
	£	£
Deposit account interest	<u>193</u>	<u>-</u>

4. Income from charitable activities

	Unrestricted	Restricted	2022 Total	2021 Total
	£	£	£	£
Pfizer Ltd	-	21,100	21,100	21,100
Online Medical Education (AstraZeneca)	-	-	-	10,000
Medical education grant (Sanofi Genzyme)	-	5,000	5,000	5,000
PSG Grant (Novartis)	-	-	-	23,800
e-learning courses (Alnylam UK Limited)	-	10,000	10,000	10,000
Growth & Development Project (Bristol- Myers Squibb Pharmaceuticals Limited)	-	62,300	62,300	59,906
Tenaya grant	<u>36,808</u>	<u>-</u>	<u>36,808</u>	<u>-</u>
Total Grants	<u>36,808</u>	<u>94,400</u>	<u>135,208</u>	<u>129,806</u>

Notes To The Financial Statements For The Year Ended 31 December 2022



5. Raising funds

Raising donations and legacies	31.12.22	31.12.21
	£	£
Staff costs	187,451	153,704
Rates and water	365	1,013
Insurance	200	422
Postage and stationery	1,094	2,157
Sundries	4,820	5,187
Event costs	46,708	64,351
Marketing	8,807	15,953
Travel and subsistence	684	32
Computer	4,009	6,223
Recruitment	5,040	550
Staff training	1,386	26
Rent	7,647	11,301
Professional fees	842	917
Donation charges	14,703	9,860
Bank charges	249	347
Subscriptions	3,823	3,674
Depreciation	1,336	876
	<u>289,164</u>	<u>276,593</u>

6. Charitable activities cost

	Direct Costs £	Grant funding of activities (see note 7) £	Totals £
Providing support	323,310	-	323,310
Public and medical education	105,058	-	105,058
Campaigning	27,389	-	27,389
Research	25,900	59,233	85,133
	<u>481,657</u>	<u>59,233</u>	<u>540,890</u>

Notes To The Financial Statements For The Year Ended 31 December 2022



7. Grants payable

	31.12.22	31.12.21
	£	£
Research	<u>59,233</u>	<u>81,882</u>

The following Grants were paid to Institutions during the year;

	2022	2021
	£	£
Alexander Janson's Myocarditis	-	1,269
AECVP Symposium	1,605	-
Global Heart Hub	-	22,985
University College London	57,628	57,628
	<u> </u>	<u> </u>
Total	<u>59,233</u>	<u>81,882</u>

8. Support costs

	Management	Governance	Totals
	£	£	£
Other resources expended	<u>56,159</u>	<u>6,000</u>	<u>62,159</u>

Analysis of support and governance costs

The charity initially identifies the costs of its support function. It then identifies those costs which relate to the governance function. Having identified its governance costs and support costs these are apportioned between the key charitable activities undertaken in the year. Please refer to the table below for the basis of apportionment and the key analysis of support.

	General Support £	Governance function £	Basis of apportionment
Wages	26,128	-	The duties to which they relate
Property related expenses	5,883	-	Floor space
General office and administration	22,558	-	Specific support costs
Legal and professional fees	-	-	Specific support costs
Bank charges	217	-	General charges
Depreciation	1,373	-	Floor space
Audit fees	-	6,000	Governance
	<u> </u>	<u> </u>	
Total	<u>56,159</u>	<u>6,000</u>	

Notes To The Financial Statements For The Year Ended 31 December 2022



9. Auditors' remuneration

The auditor's remuneration amounts to an audit fee of £6,000 (2021 - £6,500) and payroll services paid to the auditor of £936 (2021 - £864) are included in legal and professional fees.

10. Trustees' remuneration and benefits

There were no trustees' remuneration or other benefits for the year ended 31 December 2022 nor for the year ended 31 December 2021.

Trustees' expenses

There were no trustees' expenses paid for the year ended 31 December 2022 nor for the year ended 31 December 2021.

11. Staff costs

	2022 £	2021 £
Wages and salaries	488,958	464,818
Social security costs	43,314	39,087
Other pension costs	11,516	12,353
	<u>543,786</u>	<u>516,258</u>

Total redundancy / termination payments during the year amounted to £nil (2021 - £nil)

Transactions with key management personnel

	2022 £	2021 £
Total compensation of key management personnel	<u>76,081</u>	<u>71,993</u>

The average monthly number of employees during the year was as follows:

	2022	2021
	<u>18</u>	<u>18</u>

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	2022	2021
£70,001 - £80,000	<u>1</u>	<u>1</u>

Notes To The Financial Statements For The Year Ended 31 December 2022



12. Tangible fixed assets

	Computer equipment £
COST	
At 1 January 2022	33,583
Additions	1,536
	<u>35,119</u>
At 31 December 2022	35,119
DEPRECIATION	
At 1 January 2022	24,712
Charge for year	5,525
	<u>30,237</u>
At 31 December 2022	30,237
NET BOOK VALUE	
At 31 December 2022	<u>4,882</u>
At 31 December 2021	<u>8,871</u>

13. Debtors: Amounts falling due within one year

	31.12.22 £	31.12.21 £
Trade debtors	39,940	69,906
Prepayments and accrued income	225,487	174,753
	<u>265,427</u>	<u>244,659</u>

14. Creditors: Amounts falling due within one year

	31.12.22 £	31.12.21 £
Trade creditors	521	11,009
Social security and other taxes	11,684	11,353
Other creditors	2,124	2,528
Accruals and deferred income	43,620	47,115
	<u>57,949</u>	<u>72,005</u>

15. Leasing agreements

Minimum lease payments under non-cancellable operating leases fall due as follows:

	31.12.22 £	31.12.21 £
Within one year	24,200	26,400
Between one and five years	-	24,200
	<u>24,200</u>	<u>50,600</u>

Notes To The Financial Statements For The Year Ended 31 December 2022



16. Movement in funds

	At 1.1.22 £	Net movement in funds £	Transfers between funds £	At 31.12.22 £
Unrestricted funds				
General fund	393,910	123,082	(18)	516,974
Restricted funds				
Medical education	10,018	(10,018)	-	-
Youth services	1	-	-	1
Helpline	1,179	(916)	-	263
BBC Children in Need	1,968	(138)	-	1,830
Max's Foundation	650	(219)	-	431
Community Peer Support (National Lottery Community Fund)	786	(239)	-	547
Online Medical Education	3,331	(3,349)	18	-
Advocacy	39,476	22,733	-	62,209
Building the Community	11,078	(11,078)	-	-
Awareness Campaign	8,794	(8,794)	-	-
CAF Resilience Fund	9,201	2,577	-	11,778
CAF Support Fund	26,939	(22,648)	-	4,291
BMS Grant	59,631	(28,336)	-	31,295
BMS Voice	-	57,332	-	57,332
Masonic Charitable Fund	-	18,931	-	18,931
	<u>173,052</u>	<u>15,838</u>	<u>18</u>	<u>188,908</u>
TOTAL FUNDS	<u>566,962</u>	<u>138,920</u>	<u>-</u>	<u>705,882</u>

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	687,720	(564,638)	123,082
Restricted funds			
Medical education	-	(10,018)	(10,018)
Alexander Janson's Foundation	35	(35)	-
Helpline	30,000	(30,916)	(916)
BBC Children in Need	-	(138)	(138)
Max's Foundation	14,776	(14,995)	(219)
Community Peer Support (National Lottery Community Fund)	44,918	(45,157)	(239)
Online Medical Education	15,000	(18,349)	(3,349)
Advocacy	71,500	(48,767)	22,733
Building the Community	-	(11,078)	(11,078)
Awareness Campaign	-	(8,794)	(8,794)
ACT/UCL	57,628	(57,628)	-
CAF Resilience Fund	10,000	(7,423)	2,577
Burdett Trust	2,306	(2,306)	-
CAF Support Fund	14,950	(37,598)	(22,648)
BMS Grant	-	(28,336)	(28,336)
BMS Voice	62,300	(4,968)	57,332
Masonic Charitable Fund	20,000	(1,069)	18,931
	<u>343,413</u>	<u>(327,575)</u>	<u>15,838</u>
TOTAL FUNDS	<u>1,031,133</u>	<u>(892,213)</u>	<u>138,920</u>

Notes To The Financial Statements For The Year Ended 31 December 2022



16. Movement in funds - continued

Comparatives for movement in funds

	At 1.1.21 £	Net movement in funds £	Transfers between funds £	At 31.12.21 £
Unrestricted funds				
General fund	331,200	60,819	1,891	393,910
Restricted funds				
Medical education	10,018	-	-	10,018
Providing support helpline	-	1,180	-	1,180
Youth services	3,974	(3,974)	-	-
West Midlands support fund	924	-	(924)	-
Alexander Janson's Foundation	1,260	(1,260)	-	-
BBC Children in Need	4,314	(2,345)	-	1,969
Heart Hive	1,891	-	(1,891)	-
Max's Foundation	13,929	(13,278)	-	651
Community Peer Support (National Lottery Community Fund)	-	(139)	924	785
Building Capabilities (National Lottery Community Fund)	17,844	(17,844)	-	-
Online Medical Education	19,574	(16,242)	-	3,332
Advocacy	27,803	11,672	-	39,475
PPCM Campaign	4,941	(4,941)	-	-
BLF Helpline	20,572	(20,572)	-	-
Building the Community	64,490	(53,412)	-	11,078
Awareness Campaign	-	8,794	-	8,794
CAF Resilience Fund	-	9,201	-	9,201
CAF Support Fund	-	26,938	-	26,938
BMS Grant	-	59,631	-	59,631
	<u>191,534</u>	<u>(16,591)</u>	<u>(1,891)</u>	<u>173,052</u>
TOTAL FUNDS	<u>522,734</u>	<u>44,228</u>	<u>-</u>	<u>566,962</u>

Notes To The Financial Statements For The Year Ended 31 December 2022



16. Movement in funds - continued

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	553,435	(492,616)	60,819
Restricted funds			
Providing support helpline	30,000	(28,820)	1,180
Youth services	-	(3,974)	(3,974)
Alexander Janson's Foundation	10	(1,270)	(1,260)
BBC Children in Need	23,925	(26,270)	(2,345)
Max's Foundation	-	(13,278)	(13,278)
Community Peer Support (National Lottery Community Fund)	58,821	(58,960)	(139)
Building Capabilities (National Lottery Community Fund)	-	(17,844)	(17,844)
Online Medical Education	25,000	(41,242)	(16,242)
Advocacy	55,900	(44,228)	11,672
PPCM Campaign	-	(4,941)	(4,941)
BLF Helpline	-	(20,572)	(20,572)
Building the Community Awareness Campaign	23,800	(15,006)	8,794
ACT/UCL	57,628	(57,628)	-
CAF Resilience Fund	10,000	(799)	9,201
Burdett Trust	2,203	(2,203)	-
CAF Support Fund	44,850	(17,912)	26,938
BMS Grant	59,906	(275)	59,631
	<u>392,043</u>	<u>(408,634)</u>	<u>(16,591)</u>
TOTAL FUNDS	<u>945,478</u>	<u>(901,250)</u>	<u>44,228</u>

Notes To The Financial Statements For The Year Ended 31 December 2022



16. Movement in funds - continued

Medical education - Towards the costs of providing educational events and opportunities for healthcare professionals. This includes the Olsen-Gourley Lecture fund and the M Hicks Educational fund transferred from Cardiomyopathy Association.

Youth services - Towards the costs of developing and providing support services for children, youth and young adults.

Providing support helpline - Towards the costs of providing a nurse lead clinical helpline for people affected by cardiomyopathy.

West Midland support group - To provide support for those with cardiomyopathy in the West Midlands.

Alexander Janson's Foundation - To fund research into the causes, prevention and cures for myocarditis.

BBC Children in Need - To improve the emotional, physical and psychosocial (empowerment) well-being of young people under 18. Information resources (web and hard copy), paediatric helpline (out of hours), and national event, plus Panel meetings.

Heart Hive - Online platform that aims to match researchers at Imperial College with individuals interested in taking part in research trials. The objective is to seek ways of improving treatment for cardiomyopathy and myocarditis.

Community Peer Support (National Lottery Community Fund) - A five year project partly funded by the National Lottery Community Fund to develop an innovative face to face and phone peer support service for people with life limiting heart muscle disease throughout England.

Building Capabilities (National Lottery Community Fund) - National audit pan England of those NHS trusts and service providers providing clinical care and treatment to people affected by cardiomyopathy and myocarditis.

Online medical education - Towards the development of an online learning program which will improve diagnoses of cardiomyopathy and access to treatment by upskilling clinical knowledge of patient facing clinicians.



16. Movement in funds - continued

Advocacy - Developing the patient voice to affect purposeful change within the relevant statutory agencies.

PPCM campaign - To raise public awareness of peripartum cardiomyopathy in particular statutory health providers.

BLF helpline - To provide a dedicated front-line service to anyone affected by cardiomyopathy or related conditions.

Building the community - To raise awareness of Cardiomyopathy to English speaking countries internationally.

Awareness campaign - To fund a national awareness campaign aimed at raising awareness of the signs and symptoms of cardiomyopathy among hard to reach communities. This funding has been received from Novartis Pharmaceuticals UK.

CAF resilience fund - Funding to help the charity improve its ability to raise income, deliver services and develop its policy positions with the support of external consultants. This funding has been received from the Charities Aid Foundation's coronavirus emergency fund.

CAF support fund - Funding to ensure that the charity can continue

to deliver its core services and improve its ability to reach more communities and individuals affected by cardiomyopathy. This funding has been received from the Charities Aid Foundation's coronavirus emergency fund.

BMS Grant - Funding from the pharmaceutical company, Bristol Myers Squibb to cover the costs of the charity's national conference, website, outreach and awareness work.

ACT/UCL Grant - Funding from the arrhythmogenic cardiomyopathy Trust (Charity No.1176790) to fund a research project based at University College London focused on risk stratification in arrhythmogenic cardiomyopathy.

BMS patient voice - Funding from the pharmaceutical company, Bristol Myers Squibb to support a program which will use patient experiences to help shape and improve the support and treatment of cardiomyopathy.

Masonic charitable fund - 2-year grant to fund the development of the Youth Support Program.

Notes To The Financial Statements For The Year Ended 31 December 2022



17. Employee benefit obligations

The company operates a defined contribution pension scheme. The pension costs charged to the income statement represent contributions payable by the company to the fund in the year and amounted to £11,767 (2021 - £12,353).

18. Related party disclosures

There were no related party transactions for the year ended 31 December 2022.

Contact us:

-  **75a Woodside Road, Amersham, Buckinghamshire, HP6 6AA**
-  **01494 791 224**
-  **Helpline: 0800 0181024**
-  **contact@cardiomyopathy.org**
-  **www.cardiomyopathy.org**

Keep in touch:

-  **facebook.com/cardiomyopathyuk**
-  **[@cardiomyopathyuk](https://instagram.com/cardiomyopathyuk)**
-  **[@cardiomyopathy](https://twitter.com/cardiomyopathy)**
-  **youtube.com/cardiomyopathyuk**

